Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a significant increase in short interest in September. As of September 14th, there was short interest totalling 16,626,181 shares, an increase of 15.9% from the August 31st total of 14,340,210 shares. Based on an average trading volume of 2,506,604 shares, the days-to-cover ratio is presently 6.6 days. Approximately 18.5% of the shares of the stock are short sold.

Several equities analysts have recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $6.00 target price on shares of Senseonics in a research report on Thursday, August 9th. Craig Hallum began coverage on Senseonics in a report on Monday, June 11th. They issued a “buy” rating and a $7.00 price target for the company. Dougherty & Co began coverage on Senseonics in a report on Friday, August 24th. They issued a “buy” rating and a $6.00 price target for the company. Finally, Raymond James increased their price target on Senseonics from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, June 22nd. Six equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $6.00.

NYSEAMERICAN:SENS opened at $4.72 on Thursday. Senseonics has a one year low of $2.36 and a one year high of $5.29. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.81 and a current ratio of 2.93.

Senseonics (NYSEAMERICAN:SENS) last posted its quarterly earnings results on Wednesday, August 8th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.09). Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The company had revenue of $3.62 million during the quarter, compared to analyst estimates of $3.87 million. During the same period in the prior year, the business posted ($0.12) EPS. Senseonics’s revenue for the quarter was up 345.1% compared to the same quarter last year. sell-side analysts anticipate that Senseonics will post -0.54 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of SENS. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Senseonics in the second quarter valued at approximately $100,000. Thompson Davis & CO. Inc. acquired a new stake in shares of Senseonics in the second quarter valued at approximately $111,000. MetLife Investment Advisors LLC acquired a new stake in shares of Senseonics in the second quarter valued at approximately $141,000. MYDA Advisors LLC acquired a new stake in shares of Senseonics in the second quarter valued at approximately $170,000. Finally, Rhumbline Advisers acquired a new stake in shares of Senseonics in the second quarter valued at approximately $255,000. 30.66% of the stock is owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Article: S&P 500 Index

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.